Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Subject To More Oversight Following User Fee Bill Passage

This article was originally published in The Gray Sheet

Executive Summary

The legislation, awaiting the signature of the president, will bring greater scrutiny of device center activities by Congress and industry.

Advertisement

Related Content

Obamacare Repeal May Be Delaying User-Fee Bills, Rep. DeGette Says
Device Reg Issues In Play As FDA Kicks Off User Fee Renewal Effort
House Passes Compromise User Fee Bill; Senate To Vote This Week
On Eve Of User Fee Reform, Some Minnesota Firms Signal Skepticism
Final FDA Bill: Device Provisions
Congress Enters Final Stages On FDA Reform Bill
Latest Senate FDA Reform Bill Would Delay Guidance On Mobile Health Apps
CDRH Plans To Redraft Maligned 510(k) Modifications Proposal
Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees
FDA: Draft Guidance For Laboratory-Developed Test Regs Taking Extra Time

Topics

Advertisement
UsernamePublicRestriction

Register

MT031353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel